Colorectal Cancer Screening Uptake Higher With FIT-DNA Than FIT

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

THURSDAY, April 30, 2026 -- Colorectal cancer (CRC) screening participation is higher among primary care patients from community health centers receiving fecal immunochemical test (FIT)-DNA compared with those receiving FIT, according to a study published online April 27 in JAMA Internal Medicine.

Folasade P. May, M.D., Ph.D., from the University of California, Los Angeles, and colleagues compared two mailed population outreach approaches to increase CRC screening uptake among screening-eligible adults in community health centers in a pragmatic cluster randomized clinical trial. Participants were English- or Spanish-speaking primary care patients aged 45 to 75 years who were due for CRC screening. Patients received either mailed FIT with automated text message outreach from study personnel or mailed FIT-DNA with the manufacturer's outreach protocol (2,435 and 2,692 adults, respectively). Participants in randomized sites in Boston and Los Angeles with an abnormal FIT or FIT-DNA result were offered standardized navigation to colonoscopy.

The researchers found that at 90 and 180 days, screening participation was significantly higher in the FIT-DNA group than the FIT group (27.9 versus 22.6 percent and 31.7 versus 26.7 percent, respectively). Screening participation was higher at 90 days in Boston than Los Angeles (28.4 versus 23.1 percent). Overall, 36.0 percent of the 100 individuals with an abnormal stool test result completed a colonoscopy within 180 days.

"Rates of colorectal cancer are rising, but many eligible people are unscreened, especially in community health centers," coauthor Jennifer Haas, M.D., from Mass General Brigham in Boston, said in a statement. "The goal of our research was to help design an intervention to specifically benefit people who receive care in these settings."

Several authors disclosed ties to pharmaceutical and biotechnology companies, including Exact Sciences; FIT-DNA kits were provided in-kind from Exact Sciences.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-01 02:14

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords